A 55-year-old woman with LADA, class II obesity, and four concurrent autoimmune conditions—vitiligo, celiac disease, autoimmune thyroiditis, and undifferentiated arthritis—maintained stable glycemic control, significant weight loss, and preserved fasting C-peptide over five years on semaglutide without progressing to insulin dependence. Initially misdiagnosed as type 2 diabetes, the correct LADA diagnosis followed detection of anti-glutamic acid decarboxylase (anti-GAD) antibodies. Metformin was discontinued in favor of semaglutide, and even a formulary-forced switch from injectable to oral semaglutide did not disrupt metabolic stability.
LADA represents roughly 10% of all adult diabetes diagnoses yet is routinely misclassified as type 2, delaying appropriate therapy and accelerating β-cell loss. The mechanistic rationale for GLP-1 receptor agonists here is compelling: beyond glucose-lowering, preclinical and early human data suggest GLP-1RAs may exert immunomodulatory and β-cell-cytoprotective effects—plausibly slowing autoimmune destruction. That angle remains largely untested in rigorous trials. The systematic review embedded in this paper found only two comparable case reports globally, making this a near-orphan evidence base. As a single case, it can demonstrate feasibility but cannot establish causation, rule out spontaneous disease plateau, or generalize across anti-GAD titers or C-peptide levels. Still, the five-year durability without insulin is clinically meaningful. The finding is incremental but directionally important, reinforcing the urgency for prospective LADA-specific trials with GLP-1RAs before this subgroup continues being managed by default under type 2 protocols.